Latest Press Releases Press Archives CHMP CVMP COMP HMPC PDCO CAT Management Board General See also: What's New Meetings Events

Contact Point

European Medicines Agency
Press Office
7 Westferry Circus
Canary Wharf
London E14 4HB

 

Tel. +44 (0)20 7418 8427
Fax. +44 (0)20 7418 8409
press@ema.europa.eu

 

For further contact information see
Contact points

Press Office


Committee for Medicinal Products for Human Use (CHMP) Press Archive
2010
28/01/10 CHMP/35712/2010 Monthly report from the January meeting
22/01/10 CHMP/32068/2010 Press Release from the January meeting
07/01/10 CHMP/834035/2009 Monthly report from the December meeting Corr. (published 13/01/10)
 
2009
18/12/09 CHMP/833104/2009 Press Release from the December meeting Corr. (published 06/01/10)
27/11/09 CHMP/745639/2009 Monthly report from the CHMP November meeting
20/11/09 CHMP/752431/2009 Press Release from the November meeting
20/11/09 CHMP/739818/2009 Press Release - EMEA makes recommendations to minimise risk of nephrogenic systemic fibrosis with gadolinium-containing contrast agents
30/10/09 CHMP/674356/2009 Monthly report from the CHMP October meeting
23/10/09 CHMP/671190/2009 Press Release from the October meeting Corr. (published 27/10/09)
02/10/09 CHMP/599418/2009 Monthly Report from the September meeting
25/09/09 CHMP/606274/2009 Press Release from the September meeting Corr. (published 29/09/09)
30/07/09 CHMP/473955/2009 Monthly Report from the July meeting Corr. (published 31/07/09)
24/07/09 CHMP/468553/2009 Press release from the July meeting Corr. (published 27/10/09)
03/07/09 CHMP/389326/2009 Monthly Report from the June meeting
30/06/09 CHMP/367523/2009 Public statement on the recommendation to lift the suspension of the marketing authorisation for Optison (perflutren)
26/06/09 CHMP/397215/2009 Press Release from the June meeting Corr. (published 27/10/09)
26/06/09 CHMP/394741/2009 Press Release - EMEA recommends first marketing authorisation for an advanced therapy medicinal product
05/06/09 CHMP/330510/2009 Monthly Report from the May meeting
02/06/09 EMEA/328956/2009 Public statement on possible interaction between clopidogrel and proton pump inhibitors
29/05/09 CHMP/330580/2009 Press Release from the May meeting
29/05/09 CHMP/322964/2009 Press Release - EMEA recommends lifting of supply and treatment restrictions for Neupro
30/04/09 CHMP/271292/2009 Monthly report from the April meeting
23/04/09 CHMP/249660/2009 Press Release from the April meeting
26/03/09 CHMP/174243/2009 Monthly report from the March meeting
19/03/09 CHMP/172797/2009 Press Release from the March meeting
26/02/09 CHMP/97795/2009 Monthly report from the February meeting
19/02/09 CHMP/107282/2009 Press Release from the February meeting
19/02/09 CHMP/20857/2009 Press Release - EMEA recommends suspension of the marketing authorisation of Raptiva (efalizumab)
- See also - Questions and Answers on Raptiva
30/01/09 EMEA/39660/2009 Monthly Report from the January meeting
22/01/09 EMEA/37933/2009 Press Release from the January meeting Corr.
22/01/09 CHMP/22315/2009 Press Release - EMEA makes recommendations for safer use of Ritalin and other methylphenidate-containing medicines in the EU
See also - Questions and answers on the review of medicines containing methylphenidate
22/01/09 EMEA/27603/2009 Press Release - EMEA recommends new contraindication for Fareston (toremifene)
See also - Questions and answers on the addition of contraindications for Fareston (toremifene)
16/01/09 EMEA/13509/09 Press Release - Priority access for children during Myozyme supply shortage
07/01/09 EMEA/679401/08 Monthly Report from the December meeting Corr.
 
2008
19/12/08 EMEA/CHMP/670724/08 Press Release from the December meeting Corr.
17/12/08 EMEA/683633/2008 Press Release - Janssen-Cilag International N.V. withdraws its application for an extension of indication for Invega (paliperidone)
04/12/08 EMEA/645579/2008 Press Release - Oncoscience AG withdraws its application for Theraloc (nimotuzumab)
28/11/08 EMEA/612074/2008 Monthly Report from the November meeting
27/11/08 EMEA/CHMP/590563/2008 Opinion of the committee for medicinal products for human use pursuant to article 5(3) of regulation (EC) No 726/2004, on conventional antipsychotics
See also - Appendix I - CHMP Assessment Report On Conventional Antipsychotics
and - Questions and answers on the review of the use of conventional antipsychotic medicines in elderly patients with dementia
21/11/08 EMEA/CHMP/606566/2008 Press Release from the November meeting Corr. 2
20/11/08 EMEA/CHMP/613852/2008 Press Release- European Medicines Agency recommends the suspension of the marketing authorisation of Ionsys (fentanyl hydrochloride)
- See also - Questions and answers on Ionsys
31/10/08 EMEA/CHMP/539474/2008 Monthly report from the October meeting
31/10/08 EMEA/CHMP/550206/2008 Press Release from the October meeting (Rev 2)
23/10/08 EMEA/CHMP/537777/2008 Press Release - The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia
- See also - Questions and answers on Acomplia
23/10/08 EMEA/CHMP/493770/2008 Press Release - European Medicines Agency recommends first switch from prescription-only to non-prescription for a centrally authorised medicine
08/10/08 EMEA/CHMP/505537/2008 Monthly report from the September meeting
25/09/08 EMEA/CHMP/503956/2008 Press Release from the September meeting
25/09/08 EMEA/CHMP/496612/08 European Medicines Agency recommends update of product information of Tysabri and risk of progressive multifocal leukoencephalopathy (PML)
13/08/08 EMEA/CHMP/424554/2008 Press Release - European Medicines Agency update on progressive multifocal leukoencephalopathy (PML) and Tysabri
05/08/08 EMEA/417535/2008 Press Release - Pharmion Ltd withdraws its marketing authorisation application for Orplatna (INN: satraplatin)
01/08/08 EMEA/CHMP/390768/2008 Monthly Report from the July meeting
28/07/08 EMEA/388064/2008 Press Release from the July meeting (Rev. 1)
24/07/08 EMEA/CHMP/382927/2008

Press Release - European Medicines Agency recommends restricting the use of oral moxifloxacin-containing medicines
- See also - Questions and answers on the recommendation to restrict the use of oral formulations of moxifloxacin-containing medicines
24/07/08 EMEA/CHMP/382256/2008 Press Release - Studies assessed by the EMEA indicate no increased risk of developing cancer for patients who have taken Viracept contaminated with ethyl mesilate
See also - Questions and Answers on Viracept
03/07/08 EMEA/CHMP/327265/2008 Monthly Report from the June meeting
01/07/08 EMEA/CHMP/333963/2008 Press Release - EMEA recommends a new warning for epoetins for their use in cancer patients (Corr.)
26/06/08 EMEA/CHMP/333636/2008 Press Release - EMEA recommends strengthening warnings and contraindications for etoricoxib-containing medicines used in the treatment of rheumatoid arthritis and ankylosing spondylitis
26/06/08 EMEA/CHMP/322395/2008 Press Release - EMEA recommends new warnings and contraindications for ergot-derived dopamine agonists
26/06/08 EMEA/CHMP/332645/2008 Press Release from the June meeting
19/06/08 EMEA/CHMP/323118/2008 Press Release - Euro Nippon Kayaku GmbH withdraws its marketing authorisation application for Spanidin (gusperimus)
06/06/08 EMEA/CHMP/279235/2008 Monthly report from the May meeting
05/06/08 EMEA/CHMP/277722/2008 Press Release - European Medicines Agency recommends measures to manage contamination of heparin-containing medicines
- See also Questions & Answers on Heparins
02/06/08 EMEA/CHMP/278126/2008 Press Release from the May meeting
01/05/08 EMEA/CHMP/213268/2008 Monthly report from the April meeting (Corr.)
30/04/08 EMEA/CHMP/205947/2008 Press Release from the April meeting (Corr.)
24/04/08 EMEA/215870/2008 Press release - Wyeth withdraws its application to extend the marketing authorisation for Tygacil
02/04/08 EMEA/142888/2008 Press release - Further data needed to determine risk of heart attack with abacavir
- See also Q&A on Abacavir and the risk of heart attack
28/03/08 EMEA/136288/2008 Public Statement on Bextra (valdecoxib) - Non-renewal of the Marketing Authorisation in the European Union
27/03/08 EMEA/137943/2008 Monthly report from the March meeting
20/03/08 EMEA/CHMP/139489/2008 Press release EMEA concludes new advice to doctors and patients for Tysabri (natalizumab) needed
- See also Q&A on Tysabri and liver injury
20/03/08 EMEA/139443/2008 Press release - EMEA recommends new contraindication for Velcade (bortezomib)
- See also Q&A on the addition of a contraindication for Velcade (bortezomib)
20/03/08 EMEA/CHMP/140780/2008 Press release from the March meeting
04/03/08 EMEA/CHMP/95268/2008 Monthly report from the February meeting
25/02/08 EMEA/95140/2008 Press release - Actelion withdraws its application for an extension of indication for Zavesca
21/02/08 EMEA/CHMP/87277/2008 Press release from the February meeting
21/02/08 EMEA/CHMP/90694/2008 Press release - EMEA recommends authorisation of first pre-pandemic influenza vaccine
14/02/08 EMEA/60439/08 Public Statement on Risk of peripheral neuropathy with Sebivo (telbivudine)
11/02/08 EMEA/599866/07 Questions and Answers on the withdrawal of the marketing application for Sinerem
05/02/08 EMEA/37124/08 Monthly report from the January meeting
04/02/08 EMEA/4193/08 Questions and Answers on the withdrawal of the Marketing Authorisation Application for Insulin Human Rapid Marvel, Insulin Human Long Marvel and Insulin Human 30/70 Mix Marvel
01/02/08 EMEA/44714/2008

Letter from European Medicines Agency to all concerned Market Authorisation Holders on the actions needed to mitigate possible risks of contamination by alkyl mesilates, (di)isetionates, tosilates and besilates.
The published document EMEA/44714/2008 is a template of the letter to be sent out individually to each Market Authorisation Holder of a concerned Centrally Authoprised Product for human use

28/01/08 EMEA/45635/2008 Press release - Ipsen Ltd withdraws its application for an extension of indication for NutropinAq
25/01/08 EMEA/CHMP/26421/2008 Public Statement on Levviax (Telithromycin) Withdrawal of the Marketing Authorisation in the European Union
24/01/08 EMEA/CHMP/28614/2008 Press release from the January meeting
24/01/08 EMEA/33024/2008 Press release - European Medicines Agency recommends the approval of thalidomide
for the treatment of rare bone-marrow cancer
24/01/08 EMEA/42232/2008 Press release - EMEA recommends new warnings and contraindications for rosiglitazone
24/01/08 EMEA/37479/2008 Press release - EMEA statement on the safety of Gardasil
16/01/08 EMEA/2435/2008 Press release - Marvel LifeSciences Ltd withdraws its marketing authorisation applications for Insulin Human Rapid Marvel, Insulin Human Long Marvel and Insulin Human 30/70 Mix Marvel
 
2007
21/12/07 EMEA/CHMP/585637/07 Monthly Report from the December meeting
14/12/07 EMEA/583851/07 Press Release from the December meeting
27/11/07 EMEA/522109/07 Monthly Report from the November meeting
20/11/07 EMEA/541192/07 Press release - Novartis withdraws its application to extend the marketing authorisation for Zometa
21/11/07 EMEA/534678/07 Press release - European Medicines Agency recommends suspension of marketing authorisation of aprotinin-containing medicines for systemic use
- See also Q&A on the EMEA recommendation to suspend the marketing authorisation of aprotinin-containing medicines (Corr)
19/11/07 EMEA/522741/07 Public Statement on the cessation of marketing of Exubera (Insulin human)
16/11/07 EMEA/521472/07 Press release - INFAI withdraws its marketing authorisation application for Gastromotal
- See also Q&A on the withdrawal of the Marketing Application
16/11/07 EMEA/CHMP/522566/07 Press release from the November meeting (Corr. 20/11/07)
16/11/07 EMEA/5020463/07 Press release - European Medicines Agency recommends suspension of Marketing Authorisations for Carisoprodol-containing medicinal products
- See also Q&A on the recommendation to suspend the Marketing Auhorisations for Carisoprodol-containing products
16/11/07 EMEA/417458/07 Press release - EMEA recommends changes in the product information for Protelos/Osseor due to the risk of severe hypersensitivity reactions
See also Q&A on the safety of Protelos/Osseor
25/10/07 EMEA/473066/07 Monthly Report from the October meeting
23/10/07 EMEA/496188/07 Public Statement - Epoetins and the risk of tumour growth progression and thromboembolic events in cancer patients and cardiovascular risks in patients with chronic kidney disease
18/10/07 EMEA/479200/07 Press Release from the October meeting
28/09/07 EMEA/427480/07 Monthly Report from the September meeting
21/09/07 EMEA/323703/07 Press Release from the September meeting (Corr. 27/09/07)
26/07/07 EMEA/CHMP/285833/07 Public Statement on Trudexa (adalimumab) Withdrawal of the Marketing Authorisation in the European Union
25/07/07 EMEA/318931/07 Monthly Report from the July meeting
19/07/07 EMEA/431407/07 Press Release from the July meeting
29/06/07 EMEA/267656/07 Monthly Report from the June meeting
22/06/07 EMEA/267556/07 Press Release from the June meeting
25/06/07 EMEA/265144/07 European Medicines Agency recommends restricted use for Piroxicam
- See also Q&A on the review of Piroxicam
22/06/07 EMEA/CHMP/267556/07 CHMP Press Release from the June meeting
21/06/07 EMEA/275367/07 European Medicines Agency agrees on action plan following the recall of Viracept and recommends suspension of the Marketing Authorisation
- See also Q&A on the follow-up to the Viracept recall
06/06/07 EMEA/251283/07 European Medicines Agency announces recall of Viracept
- See also Q&A on the recall of Viracept
05/06/07 EMEA/CHMP/222371/07 Monthly Report from the May meeting
29/05/07 EMEA/235491/07 Protherics withdraws its marketing authorisation application for Voraxaze
25/05/07 EMEA/CHMP/231382/07 Press Release from the May meeting (Corr. 05/06/07)
24/05/07 EMEA/218760/07 Questions and Answers document on Bicalutamide 150 mg tablets
04/05/07 EMEA/CHMP/181739/07 Monthly Report from the April meeting
30/04/07 EMEA/193194/07 ISTA Pharma Ltd withdraws its marketing authorisation application for Vitragan
27/04/07 EMEA/184876/07 EMEA concludes first accelerated assessment for a medicine for human use
27/04/07 EMEA/CHMP/186566/07 Press Release from the April meeting
29/03/07 EMEA/CHMP/144134/07 Monthly Report from the March meeting
23/03/07 EMEA/CHMP/132706/07 Press Release from the March meeting
05/03/07 EMEA/79902/07 Public Statement - Baraclude (entecavir) Occurrence of a resistant HIV variant in a patient co-infected with HIV and HBV
02/03/07 EMEA/CHMP/85096/07 Monthly Report from the February meeting
23/02/07 EMEA/CHMP/82850/07 Press Release from the February meeting
02/02/07 EMEA/CHMP/521168/07 Monthly Report from the January meeting
25/01/07 EMEA/CHMP/39118/07 Press Release from the January meeting
 
2006
20/12/06 EMEA/CHMP/488156/06 Monthly Report from the December Meeting
15/12/06 EMEA/CHMP/506977/06 Press Release from the December meeting (Corrected 15/12/06, 15:30 hrs)
29/11/06 EMEA/CHMP/484273/06 Monthly Report from the November meeting
17/11/06 EMEA/CHMP/460883/06 Press Release from the November meeting (correction. Active substance corrected for two products)
27/10/06 EMEA/CHMP/410526/06 Monthly Report from the October Plenary Session
25/10/06 EMEA/CHMP/416788/06 EMEA Workshop on Neonates: Development of medicines for neonates needs multi-disciplinary cooperation
24/10/06 EMEA/CHMP/746469/06 European Medicines Agency review concludes positive benefit-risk balance for non-selective NSAIDs
- See also Q&A on the review of non-selective NSAIDs
19/10/06 EMEA/CHMP/421027/06 Press Release from the October Plenary Session
29/09/06 EMEA/CHMP/325128/06 Monthly Report from the September Plenary Session
21/09/06 EMEA/CHMP/376832/06 Press Release from the September Plenary session correction
04/08/06 EMEA/CHMP/296185/06 Monthly Report from the July Plenary Session
28/07/06 EMEA/CHMP/289040/06 Press Release from the July Plenary session
12/07/06 EMEA/CHMP/222629/06 Monthly Report from the June 2006 Plenary Session
29/06/06 EMEA/CHMP/243602/06 Press Release from the June Plenary session
14/06/06 EMEA/CHMP/209537/06 Monthly Report from the May 2006 Plenary Session
06/06/06 EMEA/CHMP/202554/06 European Medicines Agency adopts a positive opinion for the use of Prozac in the treatment of children and adolescents suffering from depression
- See also Q&A on PROZAC for use in children and adolescents
02/06/06 EMEA/CHMP/204606/06 Press Release from the May Plenary Session
01/06/06 EMEA/CHMP/192804/06 Public Statement on Infergen (Interferon alfacon-1) Withdrawal of the Marketing Authorisatoin in the European Union
12/05/06 EMEA/CHMP/111495/06 Monthly Report from the April 2006 Plenary Session Rev 1
28/04/06 EMEA/CHMP/152608/06 Press Release from the April Plenary Session
06/04/06 EMEA/CHMP/102937/06 Monthly Report from the March 2006 Plenary Session Rev 1
24/03/06 EMEA/CHMP/106554/06 Press Release from the March Plenary Session
- See also Q&A on ZELNORM
17/03/06 EMEA/CHMP/70961/06 Monthly Report from the February 2006 Plenary Session Rev 1
23/02/06 EMEA/CHMP/69276/06 Press Release from the February Plenary Session
17/02/06 EMEA/CHMP/35006/06 Monthly Report from the January 2006 Plenary Session
27/01/06 EMEA/CHMP/32796/06 Press Release from the January Plenary Session
 
2005
16/01/06 EMEA/CHMP/420100/05 Monthly Report from the December 2005 Plenary Session Rev 1
15/12/05 EMEA/CHMP/420087/05 European Medicines Agency recommends no changes for Tamiflu safety information
15/12/05 EMEA/CHMP/421484/05 Press Release from the December Plenary Session
01/12/05 EMEA/CHMP/364660/05 Monthly Report from the November 2005 Plenary Session
17/11/05 EMEA/CHMP/384581/05 Press Release from the November Plenary Session
17/11/05 EMEA/CHMP/362348/05 Revised Monthly Report from the October 2005 Plenary Session
13/10/05 EMEA/CHMP/341463/05 Press Release from the October Plenary Session Rev 1
28/09/05 EMEA/CHMP/295298/05 Monthly Report from the September 2005 Plenary Session
22/09/05 EMEA/CHMP/312626/05 European Medicines Agency statement on Herceptin
20/09/05 EMEA/CHMP/29736/05 European Medicines Agency recommends suspension of Hexavac
20/09/05 EMEA/CHMP/304888/05 Questions and Answers on the suspension of Hexavac
15/09/05 EMEA/CHMP/303099/05 Press Release from the September Plenary Session
12/08/05 EMEA/CHMP/262135/05 EMEA consulting on a draft guideline on pharmacovigilance for medicines used in children
04/08/05 EMEA/CHMP/229460/05 Monthly Report from the July 2005 Plenary Session
02/08/05 EMEA/CHMP/250423/05 Questions and Answers on non-selective NSAIDs
European Medicines Agency concludes action on COX-2 inhibitors correction
27/07/05 EMEA/CHMP/246640/05 Press Release from the July Plenary Session
08/07/05 EMEA/CHMP/207020/05 Monthly Report from the June 2005 Plenary Session
27/06/05 EMEA/CHMP/207407/05 Press Release from the June Plenary Session
07/06/05 EMEA/CHMP/160895/05 Monthly Report from the May 2005 Plenary Session correction
25/05/05 EMEA/CHMP/176508/05 Press Release from the May Plenary Session
25/05/05 EMEA/CHMP/176508/05 Press Release from the May Plenary Session
03/05/05 EMEA/CHMP/121307/05 Monthly Report from the April 2005 Plenary Session
25/04/05 EMEA/CHMP/128918/05 Press Release and Q&A correction- European Medicines Agency finalises review of antidepressants in children and adolescents
21/04/05 CHMP/138444/05 Press Release from the April Plenary Session
01/04/05 EMEA/CHMP/82984/05 Monthly Report from the March 2005 Plenary Session corr 2
17/03/05 EMEA/CHMP/96995/05 Press Release from the March Plenary Session
25/02/05 EMEA/CHMP/45462/05 Monthly Report from the February 2005 Plenary Session
17/02/05 EMEA/CHMP/59424/05 Press Release from the February Plenary Session
01/02/05 EMEA/CHMP/22735/05 Monthly Report from the January 2005 Plenary Session corr in Annex I
20/01/05 EMEA/CHMP/21979/05 Press Release from the January Plenary Session
 
2004
06/01/05 EMEA/CHMP/203834/04 Monthly Report from the December 2004 Plenary Session
16/12/04 EMEA/CHMP/199703/04 Press Release from the 13-15 December Plenary Meeting
30/11/04 EMEA/CHMP/160431/04 Monthly Report from the November Plenary Meeting
18/11/04 EMEA/CHMP/152989/04 Press Release from the 15 - 18 November Plenary Session
29/10/04 EMEA/CHMP/119155/04 Monthly Report from the October Plenary Meeting
19/10/04 EMEA/CHMP/116066/04 Press Release from the 15 -18 October 2004 Plenary Session
19/10/04 EMEA/CHMP/269/04 Monthly Report from the September Plenary Meeting
18/10/04 EMEA/CHMP/1214/04 Monthly Report from the July Plenary Meeting Corrigendum
16/09/04 EMEA/CHMP/74329/04 Press Release from the 13-16 September 2004 Plenary Session
29/07/04 EMEA/CHMP/21550/04 Press Release from the 27th -29th July 2004 Plenary Session
04/07/04 EMEA/CHMP/651/04 Monthly Report from the 22-23 June Plenary Meeting
24/06/04 EMEA/CHMP/17587/04 Press Release from the 22nd -23rd June 2004 Plenary Session
11/06/04 EMEA/CHMP/409/04 Monthly report from the 1st -3rd June 2004 Plenary Session
04/06/04 EMEA/CHMP/15358/04 Press Release from the June 2004 Plenary Session
30/04/04 EMEA/CPMP/11951/04 Monthly report from the April 2004 Plenary session
22/04/04 EMEA/CPMP/11206/04 Press Release from the April 2004 Plenary session
01/04/04 EMEA/CPMP/1238/04 Monthly report from the March 2004 Plenary session
25/03/04 EMEA/CPMP/1303/04 Press Release from the March 2004 session
04/03/04 EMEA/CPMP/0537/04 Monthly report from the February 2004 Plenary session
27/02/04 EMEA/CPMP/ 857/04 Press Release from the February 2004 session
29/01/04 EMEA/CPMP/269/04 Monthly report from the January 2004 Plenary session
22/01/04 EMEA/CPMP/406/04 Press Release from the January 2004 session
20/01/04 EMEA/CPMP/1476/04 CPMP elects new chair and vice-chair at its 100th meeting
 
2003
23/12/03 EMEA/CPMP/6016/03 Monthly report from the December session
18/12/03 EMEA/CPMP/6199/03 Press Release from the December session
03/12/03 EMEA/CPMP/5728/03 Monthly report from the November session Revision 1
20/11/03 EMEA/CPMP/5732/03 Press Release from the November session
05/11/03 EMEA/CPMP/4482/03 Monthly report from the September session Revision 2
24/10/03 EMEA/CPMP/5020/03 Monthly report from the October session
See also Presentation from the EFPIA Info Day on Performance Indicators on Pre-and Post Authorisation activities in the Centralised Procedure (Large file, 950KB)
23/10/03 EMEA/CPMP/5259/03 Press Release from the October session
25/09/03 EMEA/CPMP/4817/03 Press Release from the September session
04/09/03 EMEA/23230/03 Extraordinary meeting 3 September
01/08/03 EMEA/CPMP/3754/03 Monthly report from the July session
25/07/03 EMEA/CPMP/3971/03 Press Release from the July session
04/07/03 EMEA/CPMP/3297/03 Monthly report from the June session
27/06/03 EMEA/CPMP/16832/03 Press Release from the June session
05/06/03 EMEA/CPMP/2568/03 Monthly report from the May session Revised
22/05/03 EMEA/CPMP/2848/03 Press Release from the May session
02/05/03 EMEA/CPMP/2347/03 Monthly report from the April session
28/04/03 EMEA/CPMP/2376/03 Press Release from the April session
28/03/03 EMEA/CPMP/1358/03 Monthly report from the March session
20/03/03 EMEA/CPMP/1611/03 Press Release from the March session
03/03/03 EMEA/CPMP/3794/03 Monthly report from the February session Corrigendum
24/02/03 EMEA/CPMP/0890/03 Press Release from the February session Revised
30/01/03 EMEA/CPMP/0209/03 Monthly report from the January session
23/01/03 EMEA/CPMP/0294/03 Press Release from the January session
     
2002
06/01/03 EMEA/CPMP/6248/02 Monthly report from the December session
19/12/02 EMEA/CPMP/6589/02 Press Release from the December session
28/11/02 EMEA/CPMP/5857/02 Monthly report from the November session
21/11/02 EMEA/CPMP/5802/02 Press Release from the November session
24/10/02 EMEA/CPMP/4979/02 Monthly report from the October session
18/10/02 EMEA/CPMP/5203/02 Press Release from the October session
01/10/02 EMEA/CPMP/4634/02 Monthly report from the September session
19/09/02 EMEA/CPMP/4698/02 Press Release from the September session
31/07/02 EMEA/CPMP/3473/02 Monthly report from the July session
25/07/02 EMEA/CPMP/3677/02 Press Release from the July session
10/07/02 EMEA/CPMP/2749/02 Monthly report from the June session
27/06/02 EMEA/CPMP/3065/02 Press Release from the June session
06/06/02 EMEA/CPMP/2348/02 Press Release from the 1st CPMP Workshop for Patients' Organisations on the theme ' Information and participation'
- See also Participants' List
06/06/02 EMEA/CPMP/2222/02 Monthly report from the May session
31/05/02 EMEA/CPMP/2341/02 Press Release from the May session
28/04/02 EMEA/CPMP/8204/02 Monthly report from the April session
26/04/02 EMEA/CPMP/1747/02 Press Release from the April session
25/03/02 EMEA/CPMP/1110/02 Monthly report from the March session
21/03/02 EMEA/CPMP/7412/02 Press Release from CPMP March session
01/03/02 EMEA/CPMP/590/02 Monthly report from the February session
21/02/02 EMEA/CPMP/561/02 Press Release from CPMP February session
24/01/02 EMEA/CPMP/197/02 Monthly report from CPMP January session
17/01/02 EMEA/CPMP/4025/02 Press Release from CPMP January session
     
2001
19/12/01 EMEA/CPMP/3926/01 Monthly Report from December CPMP session
13/12/01 EMEA/CPMP/4025/01 Press Release from December CPMP session
04/12/01 EMEA/32158/01 First EMEA Workshop on Ethics in Clinical Trials
21/11/01 EMEA/CPMP/3636/01 Monthly Report from November CPMP session
16/11/01 EMEA/CPMP/3658/01 Press Release from November CPMP session
24/10/01 EMEA/CPMP/3310/01 Monthly Report from October CPMP session
19/10/01 EMEA/CPMP/3297/01 Press Release from the October CPMP Session
25/09/01 EMEA/CPMP/2936/01 Technical Report fromSeptember CPMP session
25/09/01 EMEA/CPMP/2973/01 Press Release from the September CPMP Session
31/07/01 EMEA/CPMP/2358/01 Technical Report from July CPMP session
27/07/01 EMEA/CPMP/2341/01 Press Release from the July CPMP Session
26/06/01 EMEA/CPMP/2020/01 Technical Report from June CPMP session
28/06/01 EMEA/CPMP/1935/01 Press Release from June CPMP session
07/06/01 EMEA/CPMP/1577/01 Technical Report from May CPMP session
02/05/01 EMEA/CPMP/1252/01 From April CPMP session (Full Meeting Report)
26/04/01 EMEA/CPMP/1262/01 Press Release from CPMP session (Summary)
27/03/01 EMEA/CPMP/906/01 Press Release from CPMP session
27/02/01 EMEA/CPMP/521/01 Press Release from CPMP session
31/01/01 EMEA/CPMP/250/01 Press Release from CPMP session
23/01/01 Press Release EMEA announces new CPMP chairman and vice-chairman
18/01/01 Extraordinary
CPMP press release		 CPMP Members
18/01/01 EMEA/CPMP/39663/00 Press Release: SIAMED 2000 - Speeding up drug regulation in Europe
     
2000
18/12/00 EMEA/CPMP/4305/00 Press Release
21/11/00 EMEA/CPMP/2901/00 Press Release
23/10/00 EMEA/CPMP/2849/00 Press Release
09/10/00 EMEA/22213/00 Announcement of Seminar on Pre-Clinical Safety Evaluation of Vaccines
25/09/00 EMEA/CPMP/2522/00 Press Release
27/07/00 EMEA/CPMP/1964/00 Press Release
25/07/00 EMEA/20840/00 Nomination of new Head of the Human Unit
27/06/00 EMEA/CPMP/1586/00 Press Release
31/05/00 EMEA/CPMP/1304/00 Press Release
11/04/00 EMEA/CPMP/941/00 Press Release
20/03/00 EMEA/CPMP/543/00 Press Release
15/02/00 EMEA/CPMP/316/00 Press Release
18/01/00 EMEA/CPMP/122/00 Press Release
     
1999
20/12/99 EMEA/CPMP/3323/99 Press Release
22/11/99 EMEA/CPMP/3091/99 Press Release
25/10/99 EMEA/CPMP/2769/99 Press Release
27/09/99 EMEA/CPMP/2590/99 Press Release
09/09/99 EMEA/CPMP/2325/99 Extraordinary meeting to finalise review of Anorectic Agents
30/07/99 EMEA/CPMP/2137/99 Press Release
25/06/99 EMEA/CPMP/1817/99 Press Release
25/05/99 EMEA/CPMP/1434/99 Press Release
26/04/99 EMEA/CPMP/1150/99 Press Release
29/03/99 EMEA/CPMP/841/99 Press Release
01/03/99 EMEA/CPMP/566/99 Press Release
01/02/99 EMEA/CPMP/159/99 Press Release
     
1998
21/12/98 EMEA/CPMP/2866/98 Press Release
24/11/98 EMEA/CPMP/2572/98 Press Release
26/10/98 EMEA/CPMP/2244/98 Press Release
21/09/98 EMEA/CPMP/2010/98 Press Release
27/07/98 EMEA/CPMP/1342/98 Press Release
29/06/98 EMEA/CPMP/1150/98 Press Release
29/05/98 EMEA/CPMP/975/98 Press Release
22/04/98 EMEA/CPMP/808/98 Press Release
27/03/98 EMEA/CPMP/438/98 Press Release
27/02/98 EMEA/CPMP/209/98 Press Release
30/01/98 EMEA/CPMP/069/98 Press Release
 
1997
19/12/97 EMEA/CPMP/1138/97 Press Release Rev.
20/11/97 EMEA/CPMP/1056/97 Press Release
24/10/97 EMEA/CPMP/921/97 Press Release
25/09/97 EMEA/CPMP/813/97 Press Release
25/07/97 EMEA/CPMP/651/97 Press Release
20/06/97 EMEA/CPMP/502/97 Press Release
16/05/97 EMEA/CPMP/389/97 Press Release
18/04/97 EMEA/CPMP/341/97 Press Release
21/03/97 EMEA/CPMP/234/97 Press Release
20/02/97 EMEA/CPMP/182/97 Press Release
24/01/97 EMEA/CPMP/045/97 Press Release
     
1996
18/12/96 EMEA/CPMP/1095/96 Press Release
20/11/96 EMEA/CPMP/960/96 Press Release
16/10/96 EMEA/CPMP/871/96 Press Release
11/09/96 EMEA/CPMP/741/96 Press Release
18/07/96 EMEA/CPMP/644/96 Press Release
20/06/96 EMEA/CPMP/513/96 Press Release
23/05/96 EMEA/CPMP/426/96 Press Release
- See also Annex Community Marketing Authorisations of Medicinal Products: Status on the 23rd May 1996
19/04/96 EMEA/CPMP/351/96 Press Release
14/03/96 EMEA/CPMP/285/96 Press Release
15/02/96 EMEA/CPMP/179/96 Press Release
18/01/96 EMEA/CPMP/023/96 Press Release
     
1995
21/12/95 EMEA/CPMP/938/95 Press Release
29/11/95 EMEA/CPMP/832/95 Press Release
19/10/95 EMEA/CPMP/656/95 Press Release
- See also Annex